Securian Asset Management Inc. Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Securian Asset Management Inc. lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,989 shares of the life sciences company’s stock after selling 398 shares during the quarter. Securian Asset Management Inc.’s holdings in Illumina were worth $1,602,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in Illumina by 16.4% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company’s stock worth $148,000 after acquiring an additional 156 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Illumina by 16.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 5,733 shares of the life sciences company’s stock worth $766,000 after acquiring an additional 789 shares during the last quarter. Wealthfront Advisers LLC lifted its stake in Illumina by 187.0% in the fourth quarter. Wealthfront Advisers LLC now owns 34,464 shares of the life sciences company’s stock worth $4,605,000 after acquiring an additional 22,455 shares during the last quarter. GC Wealth Management RIA LLC raised its holdings in Illumina by 9.5% during the fourth quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company’s stock worth $238,000 after purchasing an additional 154 shares in the last quarter. Finally, Citizens Financial Group Inc. RI acquired a new stake in Illumina during the fourth quarter worth approximately $205,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ILMN shares. Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada cut their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday. Citigroup lowered their price objective on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Piper Sandler lifted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $84.05 on Friday. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company’s fifty day moving average is $114.52 and its two-hundred day moving average is $130.20. The firm has a market capitalization of $13.31 billion, a P/E ratio of -10.94, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.